$PLPL one of the primary reasons why Plandai Biotechnology stood out as a potential winning investment is because of the company's recent decision to form a new division called Cannabis Biosciences. The company announced on November 1, 2013, that it planned to create a new wholly-owned subsidiary to develop and test a new Phytofare botanical extract derived from cannabis. Given that the Plandai team already has specific and unique knowledge related to bioavailability and extraction capabilities, this is likely a wise decision as the company should have significant competitive advantages over its peers in the industry who simply want to ride the waves of the medical marijuana revolution. Following a series of studies and trials, Plandai's offerings have demonstrated the highest bioavailability in the industry. In some statistics, the absorption rate into the bloodstream was more than 8 times that of competing products. Moreover, competing products and approaches do not have the validation that Plandai has received via the recently formed relationship with Diego Pellicer. It is clear that the number one brand in the cannabis industry would seek out a partnership with the company that has produced the greatest bioavailability.
(0)
(0)